Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer launches ASCO blog to talk about lung cancer

Not Just One Disease set to cover a range of topics, including the patient journey

Boehringer launches ASCO blog to talk about lung cancerStepping up its social media efforts in time for this year's American Society of Clinical Oncology (ASCO) annual meeting Boehringer Ingelheim has launched a new lung cancer-focused blog.

The Not Just One Disease blog echoes Boehringer's ongoing messaging that patient diversity in lung cancer requires personalised treatment approaches.

But the blog won't be restricted to treatment topics and the company says the patient journey, researchers' perspective and the future of lung cancer care may all feature.

The blog was introduced by a post last week from Dr Mehdi Shahidi, who is associate therapeutic area head of solid tumour oncology within Boehringer's clinical development and medical affairs team.

He wrote: “At the core of Not Just One Disease is the simple fact that cancer, and especially lung cancer, is not just one disease. There are many distinct types and subtypes, and a tailored approach to treatment can improve patient outcomes.

“Over the five day meeting itself, we will provide overviews of current activities in the field of oncology and lung cancer, and also our social media #ASCO14 picks of the day.”

The blog will feature contributions from external experts and patient group representatives alongside posts by Boehringer personnel.

The ASCO meeting is one of the biggest events in the oncology world – more than 25,000 cancer specialists are expected to attend this year, but it poses a significant challenge for pharma companies wanting to stand out from their peers.

Boehringer and others in the industry already make substantial use of Twitter for pretty much every major congress as part of their communications efforts.

GlaxoSmithKline, for example, has its @GSK_Conferences account, which features tweets from GSK employees attending scientific conferences, and Merck & Co started tweeting about ASCO 2014 nearly two months ahead of the event.

Meanwhile, dedicated sections of web sites are often developed for specific congresses, such as within Boehringer's Newshome press portal or by Genentech for its own ASCO 2014 pages.

However, Boehringer's new disease and event-specific blog may well prove to be a smart way to cut through the noise at ASCO and could also mark a further step forward on road to greater virtual participation by pharma in the big scientific congresses.

The only slight anomaly that those journeying to Chicago for ASCO 2014 may notice is that Boehringer's new blog isn't aimed at them. “Because of country-specific regulations, the blog is only intended for those outside the US and UK”, a company disclaimer runs.

21st May 2014

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Using video to enhance clinical trial patient recruitment and retention
With the clinical study landscape more competitive than ever, advertising and marketing have never been more important. They can mean the difference between successful patient recruitment and study failure. In...
DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....